Linked Life Data

18758310

Source:http://linkedlifedata.com/resource/pubmed/id/18758310

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2008-9-1
pubmed:abstractText
The use of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is considered safe in the treatment of non-small cell lung cancer. Recently, cases of erlotinib-associated interstitial lung disease have been reported. This disease entity remains poorly understood and the histopathology is rarely documented. We describe two cases of histologically confirmed fatal interstitial lung disease after erlotinib treatment for non-small cell lung cancer. After starting erlotinib treatment both patients developed clinical and radiologic signs of interstitial lung disease resulting in respiratory failure and death. Autopsy confirmed diffuse alveolar damage. As the use of erlotinib is increasing, physicians should be aware of this potentially fatal complication. The sparse data on the clinical presentation, radiographic patterns, and histologic findings of epidermal growth factor receptor tyrosine kinase inhibitor-associated interstitial lung disease are discussed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1556-1380
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1050-3
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.
pubmed:affiliation
Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands. j.lind@vumc.nl
pubmed:publicationType
Journal Article, Case Reports